Atai Life Sciences EMP-01 Phase IIa Trial Delivers Positive Topline, Shares Fall 14%
Atai Life Sciences reported positive exploratory Phase IIa topline results for its EMP-01 social anxiety disorder treatment, pushing shares down over 14% following the release. ARK Invest acquired 482,407 Atai shares valued at $1.79 million after the drop, signaling institutional confidence in the therapy’s prospects.
1. Positive Phase IIa Trial Results
Atai Life Sciences announced positive topline outcomes from its exploratory Phase IIa study of EMP-01 in social anxiety disorder, indicating that the therapy met its primary efficacy endpoint. These results pave the way for the design of larger-scale pivotal trials later this year.
2. ARK Invest Increases Stake
Following a share price decline of over 14% after the trial data release, ARK Invest purchased 482,407 Atai shares for approximately $1.79 million. The buy underscores ARK’s confidence in EMP-01’s potential despite the initial market reaction.